Peer-reviewed veterinary case report
Canine lymphoma treated with actinomycin-D chemo and maintenance
By Siedlecki, Cecile T et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2006·Bay Area Veterinary Specialists, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma received a combination of six chemotherapy drugs, including actinomycin-D, to see how well it worked and what side effects it caused. An impressive 97% of the dogs went into complete remission, with many living for over a year after treatment. While most dogs experienced mild side effects from the chemotherapy, they were manageable and didn’t last long. The study suggests that this treatment could be effective for dogs with lymphoma, especially when considering the type of lymphoma and the dog's sex.
People also search for: dog lymphoma treatment · actinomycin-D for dogs · chemotherapy side effects in dogs
Abstract
In this retrospective study, a 6-drug (prednisone, L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and actinomycin-D) chemotherapy protocol with extended maintenance for the treatment of lymphoma was evaluated for efficacy and toxicity in 39 dogs. The complete remission rate was 97%, with a median progression-free survival (PFS) of 331 d. The median overall survival (OS) was 461 d. Of the variables evaluated for prognostic significance, only immunophenotype and sex were found to be prognostic. Dogs with T-cell lymphoma had shorter PFS and OS than dogs with B-cell lymphoma. Castrated male dogs had a shorter PFS and OS than spayed female dogs. Although the majority of dogs experienced one or more episodes of chemotherapy associated toxicity, the majority of these episodes were mild and self-limiting. The results of this study warrant further investigation into the value of extended maintenance therapy and inclusion of actinomycin-D in combination chemotherapy protocols for canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16536229/